Phase 4
Completed N=40
Acetylcholinesterase Inhibitors to Improve Cognitive Function and Overall Rehabilitation After a Stroke
Cerebrovascular Accident
Source: ClinicalTrials.gov NCT00227994 ↗
Enrolled (actual)
40
Serious AEs
0.0%
Results posted
Dec 2016
Primary outcomePrimary: Physical Function (Measured by the FIM-motor) — 47.1; 49.4; 73.1; 87.4 units on a scale
Summary
This study will evaluate the effectiveness of treatment with acetylcholinesterase inhibitors in improving cognitive function and overall rehabilitation in elderly stroke survivors.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Physical Function (Measured by the FIM-motor) |
47.1; 49.4; 73.1; 87.4 | — |
| SECONDARY Medication Tolerability |
5; 5 | — |
Eligibility Criteria
Inclusion Criteria
- Admitted to a rehabilitation hospital with primary diagnosis of ischemic stroke (cardiovascular accident)
- Stroke was within 30 days of being admitted
- Medically stable
- Presence of memory and/or attentional impairments and evidence that these impairments were not present or were less severe prior to the stroke (assessed via interview with family)
- Approval by individual's attending physician at the rehabilitation hospital
Exclusion Criteria
- Aphasia or cognitive (or behavioral) impairments severe enough to prevent valid neuropsychiatric assessment
- Currently experiencing a major depressive episode (unless treated and in partial remission, assessed using the Primary Care Evaluation of Mental Disorders)
- Current psychosis or mania
- History of substance or alcohol abuse or dependence within three months of study entry
- Currently taking a cholinomimetic drug
- Medical condition with known sensitivity to donepezil (e.g., slower than normal heart rate, supraventricular cardiac conduction defects, severe asthma or obstructive pulmonary disease, active upper gastrointestinal bleed, or gastric/duodenal ulcer if not on acid-blocking agent)
- Informed that taking donepezil is medically inadvisable
- Current use of any anticholinergic medication (e.g., for bladder spasm)
Data sourced from ClinicalTrials.gov (NCT00227994). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.